GH Research PLC (GHRS)
NASDAQ: GHRS · Real-Time Price · USD
14.68
-0.46 (-3.04%)
At close: Apr 7, 2026, 4:00 PM EDT
14.73
+0.05 (0.33%)
After-hours: Apr 7, 2026, 4:10 PM EDT
GH Research Employees
GH Research had 73 employees as of December 31, 2025. The number of employees increased by 23 or 46.00% compared to the previous year.
Employees
73
Change (1Y)
23
Growth (1Y)
46.00%
Revenue / Employee
n/a
Profits / Employee
-$661,068
Market Cap
910.59M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 73 | 23 | 46.00% |
| Dec 31, 2024 | 50 | 1 | 2.04% |
| Dec 31, 2023 | 49 | 17 | 53.13% |
| Dec 31, 2022 | 32 | 18 | 128.57% |
| Dec 31, 2021 | 14 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Fortrea Holdings | 14,300 |
| Phathom Pharmaceuticals | 371 |
| UroGen Pharma | 291 |
| Xencor | 260 |
| MapLight Therapeutics | 133 |
| Inhibrx Biosciences | 110 |
| Janux Therapeutics | 109 |
| Cullinan Therapeutics | 109 |
GHRS News
- 13 days ago - GH Research Announces Publication of Phase 2b Results for Mebufotenin (GH001) in JAMA Psychiatry and Reports New Finding of Severity-Independent Efficacy in TRD - GlobeNewsWire
- 4 weeks ago - GH Research Reports Full Year 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 3 months ago - FDA Lifts Hold On GH Research's Depression Drug Trial After Two Years - Benzinga
- 3 months ago - GH Research Announces FDA Lifts Clinical Hold on GH001, Clearing Path for Global Phase 3 Initiation in 2026 - GlobeNewsWire
- 3 months ago - GH Research to Announce IND Status for GH001 - GlobeNewsWire
- 5 months ago - GH Research Reports Third Quarter 2025 Financial Results and Provides Business Updates - GlobeNewsWire
- 6 months ago - Depression-Focused GH Research Shares Could See Significant Upside: Analyst - Benzinga
- 6 months ago - GH Research Announces Novel Therapies Symposium Presentation and Posters at the 2025 ECNP Congress - GlobeNewsWire